Mana.bio Appoints Gene Therapy Pioneer Laura Sepp-Lorenzino to Scientific Advisory Board
核心洞察
Mana.bio (搜索) has appointed Dr. Laura Sepp-Lorenzino, former CSO of Intellia Therapeutics, to its Scientific Advisory Board to guide the company's AI-driven LNP discovery platform.
Dr. Sepp-Lorenzino brings decades of leadership experience from Intellia, Vertex Pharmaceuticals, Alnylam, and Merck, spanning CRISPR, RNAi, and nucleic acid therapies.
Mana.bio (搜索)'s proprietary AI/ML platform leverages the world's largest curated LNP dataset to predict safety, tropism, and stability, with NHP-validated delivery solutions for extrahepatic targets.
Mana.bio (搜索), a biotechnology company focused on revolutionizing targeted RNA delivery through artificial intelligence-enabled lipid nanoparticle (LNP) discovery and optimization, has appointed Laura Sepp-Lorenzino, Ph.D., to its Scientific Advisory Board. The announcement, made July 27, 2026, marks a strategic addition as the company accelerates development of its AI-driven genetic medicine platform.
"We are honored to welcome Laura to our Scientific Advisory Board at this pivotal stage of our company's growth," said Yogev Debbi, Co-Founder and CEO of Mana.bio (搜索). "Laura is a pioneer in the field of genetic medicine, having overseen some of the most significant breakthroughs in the industry. Her deep scientific fluency and experience in moving complex modalities from early research through clinical development will be invaluable as we continue to scale our AI-driven LNP discovery engine and expand our therapeutic pipeline."
A Distinguished Career in Genetic Medicines
Dr. Sepp-Lorenzino most recently served as Chief Scientific Officer of Intellia Therapeutics, where she played a pivotal role in advancing the company's CRISPR-based pipeline. Prior to Intellia, she held leadership positions at Vertex Pharmaceuticals as Head of Nucleic Acid Therapies, and at Alnylam Pharmaceuticals (搜索), where she led hepatic infectious disease programs and served as Entrepreneur-in-Residence. She began her industrial career at Merck & Co. (搜索), leading RNAi and oncology drug discovery efforts.
Her current board and advisory commitments span the gene and cell therapy landscape. Dr. Sepp-Lorenzino serves on the board of directors of Taysha Gene Therapies, Asklepios Biopharmaceutical (搜索) (AskBio), Lexeo Therapeutics, and URSA Medicines. She also holds leadership roles within the Oligonucleotide Therapeutics Society (OTS), where she is President Elect, and the American Society of Cell and Gene Therapy (ASGCT). Additionally, she serves on the scientific advisory boards of ThermoFisher Scientific (搜索), Galtec, and Inverna Therapeutics, and is an editorial board member of Nucleic Acid Therapeutics and Molecular Therapy Nucleic Acids.
Dr. Sepp-Lorenzino holds a professional degree in Biochemistry from the University of Buenos Aires, Argentina, and earned her M.S. and Ph.D. in Biochemistry from New York University.
Mana.bio (搜索)'s AI-Enabled LNP Platform
Mana.bio (搜索) is built on what it describes as the world's largest curated LNP dataset, combined with proprietary AI models capable of predicting key determinants of safety, tropism, and physicochemical stability. The company's AI/ML platform has generated multiple proprietary delivery solutions with non-human primate (NHP) validation, enabling tissue-specific delivery of nucleic acid therapeutics across a wide range of extrahepatic organs and cell types.
A critical differentiator is the company's predictive safety model, designed to de-risk LNP design in early development—a bottleneck that has historically constrained the advancement of RNA therapeutics. By addressing safety concerns earlier in the development process, Mana.bio (搜索) aims to accelerate the translation of genetic medicines from discovery to the clinic.
Founded in Tel Aviv, Israel, Mana.bio (搜索) is backed by Andreessen Horowitz Bio + Health, Base4 Capital, NFX, LionBird, Entrée Bio, and the Technion – Israel Institute of Technology.